Vahid M Harandi
Overview
Explore the profile of Vahid M Harandi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golonka W, Raschka C, Harandi V, Domokos B, Alfredson H, Alfen F, et al.
J Clin Med
. 2021 Jun;
10(11).
PMID: 34070780
(1) Background: Reconditioning of the paraspinal lumbar extensor muscles by isolated lumbar extension resistance exercises (ILEX) has shown good clinical results for patients with chronic unspecific low back pain. However,...
2.
Harandi V, Oliveira B, Allamand V, Friberg A, Fontes-Oliveira C, Durbeej M
Antioxidants (Basel)
. 2020 Mar;
9(3).
PMID: 32197453
Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe neuromuscular disorder without a cure. Using transcriptome and proteome profiling as well as functional assays, we previously demonstrated significant...
3.
Fontes-Oliveira C, M Soares Oliveira B, Korner Z, Harandi V, Durbeej M
Sci Rep
. 2018 Nov;
8(1):16302.
PMID: 30389963
Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe muscle disorder with complex underlying pathogenesis. We have previously employed profiling techniques to elucidate molecular patterns and demonstrated significant...
4.
Gawlik K, Harandi V, Cheong R, Petersen A, Durbeej M
Matrix Biol
. 2018 Mar;
70:36-49.
PMID: 29544677
Muscular dystrophies, including laminin α2 chain-deficient muscular dystrophy (LAMA2-CMD), are associated with immense personal, social and economic burdens. Thus, effective treatments are urgently needed. LAMA2-CMD is either a severe, early-onset...
5.
Harandi V, Gaied A, Brannstrom T, Pedrosa Domellof F, Liu J
Invest Ophthalmol Vis Sci
. 2016 Dec;
57(15):6831-6842.
PMID: 28002846
Purpose: To investigate the impact of amyotrophic lateral sclerosis (ALS) on the extraocular muscles (EOMs) by examining the distribution of neurotrophic factors (NTFs) and their receptors in EOMs and limb...
6.
Harandi V, Lindquist S, Kolan S, Brannstrom T, Liu J
PLoS One
. 2014 Oct;
9(10):e109833.
PMID: 25334047
Amyotrophic lateral sclerosis (ALS) is currently an incurable fatal motor neuron syndrome characterized by progressive weakness, muscle wasting and death ensuing 3-5 years after diagnosis. Neurotrophic factors (NTFs) are known...
7.
McLoon L, Harandi V, Brannstrom T, Andersen P, Liu J
Invest Ophthalmol Vis Sci
. 2014 Aug;
55(9):5482-96.
PMID: 25125606
Purpose: The extraocular muscles (EOM) and their motor neurons are spared in amyotrophic lateral sclerosis (ALS). In limb muscle, axon retraction from the neuromuscular junctions occurs early in the disease....